Highthink Med closes Series B financing round

Highthink Med announced that it has completed the Series B financing round, and the investor and the amount of financing were not disclosed. The company said that the clinical research business suspended due to the impact of the Covid-19 pandemic has been fully relaunched, and the development driven by the two wheels of business and capital has accelerated.

Highthink Med announced that it has completed the Series B financing round, and the investor and the amount of financing were not disclosed. The company said that the clinical research business suspended due to the impact of the Covid-19 pandemic has been fully relaunched, and the development driven by the two wheels of business and capital has accelerated.

Beijing-based Highthink Med was established in 2006. The company is a contract research organization (CRO) specialized in providing Phase I–IV clinical research and related technical services for pharmaceutical companies, medical device companies and new drug research institutions.

With the soaring cost of drug research and development in the world, the driving of drug patent cliffs and China’s accession to ICH, the value of a CRO company with a high degree of specialization, standardization, scale, and rich project practical experience is quickly highlighted.

Highthink Med, in the context of the country’s policy of encouraging innovation, provides one-stop comprehensive professional technical services and solutions.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/03/highthink-med-closes-series-b-financing-round/.

Leave a Reply

Your email address will not be published. Required fields are marked *